PMID

Data

Article Title

Organization

Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.

Boehringer Ingelheim Pharmaceuticals

Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.

Arena Pharmaceuticals

The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.

Eli Lilly

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.

Arena Pharmaceuticals

Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB(2) cannabinoid receptor partial agonists.

Universit£

Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.

Nycomed Pharma

7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.

Universit£

Discovery and optimization of novel purines as potent and selective CB2 agonists.

Eli Lilly

Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB2 receptor agonists for pain management.

Abbott Laboratories

Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.

University of Bonn

Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

Amgen

Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.

Taisho Pharmaceutical

Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.

Merck Research Laboratories

Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

Merck Research Laboratories

Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.

Merck Research Laboratories

Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.

National Institute of Radiological Sciences

Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.

Adolor

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.

Abbott Laboratories

Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.

Adolor

New resorcinol-anandamide"hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.

Universita Degli Studi Di Siena

Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.

Monash University (Parkville Campus)

Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.

Glaxosmithkline

Structure-Based Design, Optimization, and Development of [

Helmholtz-Zentrum Dresden-Rossendorf (Hzdr)

Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.

Utrecht University

Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Instituto De Qu£Mica M£Dica

Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.

Biological Research Centre of The Hungarian Academy of Sciences

Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.

Kennesaw State University

Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.

Zhejiang University

Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.

Lilly Research Laboratories

Discovery of novel tetrahydro-pyrazolo [4,3-c] pyridines for the treatment of neuropathic pain: synthesis and neuropharmacology.

Birla Institute of Technology & Science - Pilani

Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.

Universit£

Discovery of APD371: Identification of a Highly Potent and Selective CB

Arena Pharmaceuticals

In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.

Japan Tobacco

ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.

Abbott Laboratories

Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.

Virginia Commonwealth University

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Sanofi Recherche